Search Results for: LAM Therapeutics Announces Progress of
Articles
Jupiter Orphan Therapeutics Announces IND Submission for Mucopolysaccharidosis Type-I March 14, 2018
Jupiter Orphan Therapeutics, Inc. recently announced it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis...Akari Therapeutics Announces Completion of Phase II Trial February 13, 2018
Akari Therapeutics, Plc recently announced additional data for its Phase II COBALT clinical trial and provides an update on other...Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study November 28, 2017
Aptevo Therapeutics Inc. recently announced recent developments related to the Company’s novel ADAPTIR bispecific antibody platform, including the planned commencement...Protalix BioTherapeutics Announces New Preclinical Results April 24, 2017
Protalix BioTherapeutics, Inc. recently announced new, promising results from a preclinical trial conducted in collaboration with Prof. Raphael Schiffmann, Director,...Selecta Biosciences Announces Preclinical Data Showing Potential Benefit in Treatment of Pompe Disease February 20, 2017
Selecta Biosciences, Inc. recently announced that results from preclinical studies involving the use of SVP-Rapamycin in combination with alglucosidase alfa...Kamada Announces Plan for Phase II/III Clinical Trial November 8, 2016
Kamada Ltd. recently announced the clinical plan for the initiation of a Phase II/III clinical trial in the United States...CymaBay Therapeutics Announces Newly Issued US Patent for the Treatment of NAFLD & NASH October 17, 2016
CymaBay Therapeutics, Inc. recently announced that the US Patent and Trademark Office has issued US Patent No. 9,381,181. This patent...Soligenix Announces Initiation of Pivotal Phase III Clinical Trial December 15, 2015
Soligenix, Inc. recently announced that patient enrollment has been opened for its Phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating...DURECT Corporation Announces Positive Study Results May 20, 2015
DURECT Corporation recently announced it has obtained positive results from a multi-dose Phase I clinical trial with an oral formulation...Eleven Biotherapeutics Announces Top-Line Results From Pivotal Phase III Study May 20, 2015
Eleven Biotherapeutics, Inc. recently announced top-line results from the OASIS study, the company’s first pivotal Phase III study of its...THERAPEUTIC FOCUS - TTHX1114: Improving Outcomes for High-Risk Patients After Cataract Surgery February 28, 2024
David Eveleth, PhD, says in many cases, high-risk patients have few options for complication-free treatment of cataracts or other degenerative eye disorders. By filling this unmet need, TTHX1114 has the potential to significantly improve vision health, enhance the well-being of high-risk individuals, and alleviate economic burden on healthcare systems and economies.
GALECTIN INHIBITORS - Is a Galectin-3 Inhibitor the Answer for Millions of Patients With Cirrhosis & Cancer? January 14, 2022
Pol F. Boudes, MD, explains how development of a galectin-3 inhibitor could play a significant role in treating liver diseases, such as non-alcoholic steatohepatitis (NASH) and its complication, liver cirrhosis.
APTAMER TECHNOLOGY - From Postal Codes to GPS: Building Better Drug Conjugates With Aptamers November 30, 2021
David Bunka, PhD, and Emily Robinson, PhD, focus on a new breed of affinity binders that can be used as an alternative to antibody therapeutics and has the potential to reshape the industry, delivering new medicines with improved safety and efficacy profiles and reduced healthcare costs.
DRUG DEVELOPMENT - Cell & Gene Therapies Calling for Innovation in Drug Development August 27, 2018
Lev Gerlovin and Pascale Diesel, PharmD, believe there is significant evidence to indicate that we are entering a golden age of gene and cell therapy development, and while industry works to advance these programs, the debate over new approaches in both structuring and financing clinical research is likely to continue.
THERAPEUTIC FOCUS - GSNOR Inhibition to Stabilize & Improve Mutant CFTR Processing February 27, 2017
Steven Shoemaker, MD, reviews how cavosonstat represents a safe and effective option for patients with CF with at least one copy of the F508del-CFTR mutation; and that when used with correctors and potentiators, improves patient outcomes including lung function.
FORMULATING PEPTIDES - Novel Formulations for Non-Invasive Delivery & Stabilization of Peptides October 15, 2013
Edward T. Maggio, PhD, examines how alkylsaccharides offer exciting prospects for novel formulations, providing non-invasive delivery, stabilization, and immunogenicity reduction for biotherapeutic products, resulting in broader patient acceptance and compliance and an increase in their acceptance as viable commercial pharmaceuticals.
2/13/2013 February 11, 2013
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders The range of potential...11/28/2012 November 26, 2012
CoreRx & ViroPro Announce Agreement CoreRx, Inc. and Viropro, Inc. recently announced the two companies have entered into a Reciprocal...9/12/2012 September 10, 2012
Cobra Biologics & Algeta Sign Monoclonal Antibody Agreement Cobra Biologics Ltd and Algeta ASA recently announced a new contract manufacturing...4/10/2012 April 8, 2012
Catalent & BASF Join Forces to Solve Bioavailabilty Challenges Catalent Pharma Solutions and BASF recently announced they have entered into...
